Lymphatic malformation
Therapeutic area
Vascular Medicine
Rare disease
No
- Definition
- Primary lymphedema is caused by anatomic or functional defects in the lymphatic system, resulting in chronic swelling of body parts and lymphatic-system malformation.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Lymphatic malformation
- Therapeutic area
- Vascular Medicine
- lymphatic malformation
- hereditary lymphedema
- Lymphatic Malformation, Low Flow
- lymphedema, hereditary
- Severity
- Moderate
- Genetic
- Hereditary
Sources for recorded values
- Cardiology
- Hematology
- Immunology
- Vascular Medicine
Sources for recorded values
- MONDO ID
- MONDO:0019313
- Parent condition
- MONDO:0003847
Related records
Broader conditions (13)
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Human disease
- Immune system disorder
- Lymphatic system disorder
- Lymphedema
- Lymphoid system disorder
- Primary lymphedema
- Vascular disorder
Narrower conditions (47)
- Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome
- Campomelia, Cumming type
- Congenital primary lymphedema of Gordon
- Dahlberg-Borer-Newcomer syndrome
- Deafness-lymphedema-leukemia syndrome
- Hennekam lymphangiectasia-lymphedema syndrome 1
- Hennekam lymphangiectasia-lymphedema syndrome 2
- Hennekam lymphangiectasia-lymphedema syndrome 3
- Hennekam syndrome
- Hypotrichosis-lymphedema-telangiectasia syndrome
- Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome
- Lymphatic malformation 1
- Lymphatic malformation 10
- Lymphatic malformation 11
- Lymphatic malformation 12
- Lymphatic malformation 13
- Lymphatic malformation 14
- Lymphatic malformation 2
- Lymphatic malformation 3
- Lymphatic malformation 4
Trials (42)
- A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
- A Prospective Natural History Study of Lymphatic Anomalies
- A Prospective Study on the Treatment of cLM Based on ICG Imaging
- A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
- A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
- Airway Vascular Lesions
- Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
- Apple Peptide Complex for Post-Surgical and Aesthetic Skin Recovery
- Bleomycin as an Effective and Curative Adjunct Therapy for Lymphangioma
- Bleomycin Intralesional Injections of Cystic Hygromas
- Clinical Characteristics of Lymphatic Malformations
- Diagnosis of Hemangiomas and Vascular Malformations
- Diagnostic Imaging of Vascular Malformations Using MSOT and ULM
- Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
- Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations
- European Registry Study on Lymphatic Interventions
- First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations
- Indocyanine Green Lymphography in Management of Lingual Lymphatic Malformation
Drugs in development (7)
- Alpelisib Phase 2
- Bleomycin Phase 2
- Doxycycline Phase 2
- OSI-027 Phase 1
- Selenium Phase 1
- Sildenafil Phase 2
- Sirolimus Phase 3